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The proneness-persistence-impairment (PPI) model states that psychotic experiences are more likely to lead to
impairment if their expression becomes persistent. Higher genetic risk for psychosis is known to affect proneness
and persistence of subclinical positive symptoms. Less is known about potential effects of genetic risk on the
course of subclinical negative symptoms, impairment, and their subsequent associations. The current study ex-
amined these issues in a large sample (n = 1131), consisting of individuals with higher genetic risk (siblings
of patients with psychotic disorders, n = 703) and lower genetic risk (controls without a family member with
lifetime psychosis, n = 428). Psychotic experiences were assessed with the CAPE questionnaire, at two time
points three years apart. Participants were allocated to one of four groups representing developmental course:
stable low, decreasing, increasing or persisting subclinical positive/negative symptoms. Lifetime clinical psycho-
sis was an exclusion criterion at baseline. Higher genetic risk status was found to be associated with a persisting
course of both subclinical positive and negative symptoms, symptom-related distress and functional impairment.
There is no evidence for an effect of genetic risk status on the association between developmental course and im-
pairment. The results of the current study underline the importance of assessing psychotic experiences in the
context of genetic risk, multidimensional and over time. Additionally, the current ﬁndings both underscore
and contribute to the PPI model: psychotic experiences are more likely to lead to impairment if their expression
becomes persistent, both in individuals with higher and lower genetic risk for psychosis.
© 2016 Published by Elsevier B.V.
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1. Introduction
Subclinical manifestations of the psychosis phenotype, also re-
ferred to as psychotic experiences, are found to be present in the
general population with prevalence rates ranging up to 17.5% (Van
Os et al., 2009). Studies often use the term ‘psychotic experiences’ in-
terchangeably with a multitude of other terms all developed to
reﬂect vulnerability for schizophrenia-spectrum pathology, such as
‘psychotic-like experiences’, ‘subclinical psychotic symptoms’,
‘schizotypy’, ‘schizotypical symptoms’, ‘psychosis-proneness’ and
‘attenuated psychotic symptoms’ (Kwapil and Barrantes-Vidal,
2015). In the current study we choose to use the term psychotic ex-
periences, deﬁned as multidimensional (including both subclinical
positive and negative psychotic symptoms) psychometric risk for
psychosis based on the Community Assessment of Psychic Experi-
ence (CAPE; www.cape42.homestead.com), a reliable and valid
self-report questionnaire for dimensions of psychotic experiences
in non-clinical samples (Konings et al., 2006).
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Findings of large general population studies show that for the vast
majority of people, estimated between 75% and 90% (Van Os et al.,
2009), psychotic experiences are transient and not indicative of need
for care (Hanssen et al., 2005; Linscott and van Os, 2013). A minority
of individuals, on the other hand, will make a transition to clinical
psychosis, with an estimated prevalence rate around 4% (Van Os et al.,
2009). The proneness-persistence-impairment model of psychotic dis-
orders states that the transition from psychotic experiences to clinical
psychosis is preceded by the persistence of psychotic experiences and
is accompanied by increasing impairment, depending on additional
risk factors (Cougnard et al., 2007; Van Os et al., 2009). Previous re-
search has indeed demonstrated that persistence of psychotic expe-
riences is associated with transition to clinical psychosis and/or need
for care (Cougnard et al., 2007; Dominguez et al., 2011; Wigman
et al., 2011a; Wigman et al., 2011b) as well as functional impairment
(Dominguez et al., 2011; Kaymaz et al., 2012; De Loore et al., 2011;
Rossler et al., 2007; Wigman et al., 2011b). Moreover, in a cohort of
adolescents progressively stronger associations with severity of
psychotic experiences, symptom-related distress and functional im-
pairment have been reported for respectively a stable low, decreas-
ing, increasing and persisting trajectory of psychotic experiences
(Wigman et al., 2011b).
However, studies focusing on the temporal course of psychotic expe-
riences in non-clinical samples have almost exclusively focused on the
subclinical manifestation of the positive symptom dimension of psy-
chotic disorders: delusional ideation and perceptual anomalies. There
is indication that the negative symptom dimension of psychotic disor-
ders, consisting of symptoms such as blunted affect and avolition, is
also present in the general population in attenuated forms (Maric
et al., 2004, Stefanis et al., 2002). Furthermore, there is evidence for fa-
milial liability between subclinical and clinical expressions of both the
positive and the negative symptom dimension of psychosis (Fanous
et al., 2001; Lataster et al., 2014).
Subclinical negative psychotic symptoms (from here-on referred to
as ‘negative symptoms’) are clinically relevant, as they are predictive
of onset of clinical psychosis (Demjaha et al., 2012; Valmaggia et al.,
2013), mental health care use (Dominguez et al., 2011; Maric et al.,
2004) and functional impairment (Cohen and Davis, 2009; Dominguez
et al., 2011; Kwapil et al., 2013), independent of subclinical positive
psychotic symptoms (from here-on referred to as ‘positive symptoms’).
Additionally, there is indication of added value in assessing the course of
negative symptoms over time, as the persistence of negative symptoms
has been found to predict the onset and persistence of positive symp-
toms, and particularly their co-occurrence is found to predict help-
seeking behaviour and dysfunction due to symptoms (Dominguez
et al., 2010).
Previous research has shown that exposure to environmental risk
factors such as childhood trauma (Read et al., 2005), cannabis use
(Moore et al., 2007) and an urban environment (Krabbendam and van
Os, 2005), increase the risk of persistence of positive symptoms in the
general population (Cougnard et al., 2007). With regard to genetic
risk, prior research in a general population female twin-sample has in-
dicated genetic factors in the early prevalence of positive symptoms
(Lataster et al., 2009a), and in particular a substantial genetic contribu-
tion to the persistence of positive symptoms is found (Wigman et al.,
2011a). Dominguez et al. (2010) found indication for differences in
risk factors between positive and negative symptoms in a non-clinical
sample of adolescents and young adults: positive symptoms were
found to be associated with environmental exposures, such as trauma
and cannabis use, whereas negative symptomswere found to be associ-
ated with a pattern of socio-demographic associations possibly indica-
tive of earlier developmental impairment, such as younger age and
low education. These ﬁndings lead Dominguez et al. (2010) to hypoth-
esize that genetic vulnerability and abnormal brain development may
particularly drive the persistence of negative symptoms. In studies
using variants of the schizotypy construct, the contribution of genetic
factors to both the positive and negative symptom dimension is a
well-established fact (e.g. Kendler et al., 1995).
In summary, ﬁndings of previous studies in non-clinical samples
provide evidence that genetic risk for psychosis affects the proneness
to and persistence of positive symptoms. To a lesser degree, there is in-
dication for a contribution of genetic risk to the developmental course of
negative symptoms. In addition, proneness to and persistence of both
positive and negative symptoms are suggested to independently predict
clinical and functional impairment. No studies to date have focused on
the contribution of genetic risk to the relation between course of
psychotic experiences and clinical and functional impairment.
The current study aims to replicate ﬁndings of previous studies re-
garding proneness and persistence of psychotic experiences, and aims
to expand on previous studies by investigating a plausible genetic con-
tribution to the proneness-persistence-impairment model, separate for
positive and negative symptoms. To fulﬁl these aims, we examined as-
sociations between genetic risk status, the (three year) course of posi-
tive and negative symptoms and clinical and functional impairment in
a large non-clinical sample, consisting of siblings of patients diagnosed
with a psychotic disorder (representing higher genetic risk status for
psychosis) and healthy controls without a ﬁrst degree family member
with a psychotic disorder (representing lower genetic risk status for
psychosis). Clinical impairment is deﬁned as symptom-related distress
and transition to clinical psychosis. Functional impairment is deﬁned
in terms of social functioning and subjective quality of life. It was
expected that (1) individuals with a higher genetic risk for psychosis
(siblings) are more likely to experience a persistent course of both
positive and negative symptoms compared to individuals with lower
genetic risk (controls), (2) higher genetic risk status for psychosis
(sibling status) predicts higher levels of clinical and functional impair-
ment, (3) persistent course of both positive and negative symptoms in-
dependently predict higher levels of clinical and functional impairment,
(4) the association between persistent course and impairment is more
pronounced in individuals with a higher genetic risk status (siblings)
compared to individuals with a lower genetic risk (controls).
2. Methods
2.1. Participants and procedures
Data pertain to the baseline and follow-up measure of the GROUP
(Genetic Risk andOutcome of Psychosis) study, an ongoing longitudinal
multicenter cohort study (for details see Korver et al., 2012). For the cur-
rent study, only sibling- and healthy control-data were used. Partici-
pants were recruited in selected geographical areas in the Netherlands
and Belgium. Inclusion criteria were: (i) age between 16 and 50 years,
(ii) good command of the Dutch language, (iii) being able and willing
to give informed consent. Siblings had a brother or sister meeting the
DSM-IV-TR (APA, 2000) criteria for a non-affective psychotic disorder.
Siblings were not allowed to meet criteria for a lifetime diagnosis of
any psychotic disorder at baseline. Healthy control participants had no
lifetime diagnosis of a psychotic disorder at baseline and no ﬁrst-
degree relative with a lifetime psychotic disorder. The standing ethics
committee approved the study, and all the subjects gave written
informed consent in accordance with the committee's guidelines.
2.2. Measures
2.2.1. Developmental course of psychotic experiences
Psychotic experiences (from hereon: PE) were assessed with the
self-report questionnaire Community Assessment of Psychic Experience
(CAPE; www.cape42.homestead.com). Studies using the CAPE in gener-
al population samples have shown good psychometric properties in
terms of reliability and validity (Konings et al., 2006). The CAPE positive
and negative symptom frequency scales were used for analyses. The de-
velopmental course of PE was based on the presence or absence of high
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PE at baseline (lifetimepresence) and (3-year) follow-up (interval pres-
ence), reﬂected in a mean score in the fourth quartile on the CAPE fre-
quency scales, assessed for positive and negative symptoms
separately. Cut-offs for positive and negative symptoms were
resp. 0.31 and 0.72 at baseline, and 0.15 and 0.65 at follow-up. Partici-
pants were allocated to one of four groups representing developmental
course: (0) stable low: high PE absent at both time points, (1) decreasing:
high PE present at baseline but absent at follow-up, (2) increasing: high
PE absent at baseline but present at follow-up, and (3) persistent: high
PE present at both time points.
2.2.2. Clinical outcome
Transition to clinical psychosiswas deﬁned as the onset ofﬂorid psy-
chotic symptoms (hallucinations, delusions, formal thought disorder
and/or inappropriate/bizarre behavior), between baseline and follow-
up, fulﬁlling DSM-IV criteria (APA, 2000) for a psychotic disorder as
assessed by the Comprehensive Assessment of Symptoms and History
(CASH; (Andreasen et al., 1992) at follow-up. For more details on
criteria for transition to clinical psychosis we refer to Van Nierop et al.
(2013). Overall symptom-related distress was assessed with the CAPE,
based on the sumof positive, negative and depressive symptomdistress
scales, with higher scores reﬂectingmore distress (range per item: 0–3,
20 items for thepositive subscale, 14 items for thenegative subscale and
8 items for the depressive subscale).
2.2.3. Functional outcome
Social functioning was assessed using the Social Functioning Scale
(SFS) (Birchwood et al., 1990), a widely used instrument to measure
areas of functioning essential for successful community maintenance.
The total score on the SFS was used as a measure of overall social func-
tioning in the past three months. Higher scores on the SFS indicate
higher levels of social functioning (range: 93.36–134.93). The World
Health Organization Quality of Life (WHOQOL-BREF; (WHO, 1998)
was used to rate subjective quality of life (QoL) over the past two
weeks. The sum score of the four domains (physical, psychological, so-
cial and environmental) was used, with higher scores reﬂecting better
QoL (range: 26–130).
2.3. Analyses
Analyseswere run using Stata, version 12 (Statacorp, 2011).We ﬁrst
investigated the association between genetic risk status and the devel-
opmental course of positive/negative subclinical symptoms.Multinomi-
al logistic regression analyses were run using the MLOGIT command.
Genetic risk status (lower risk (healthy controls): 0 vs. higher risk (sib-
lings): 1) was used as independent variable and the developmental
course of positive/negative symptoms as dependent variable. In Model
1, age and gender were added as possible confounders. Also, the course
of negative symptoms was added as covariate in the model of positive
symptoms and vice versa (Model 2). As observations of individuals
within the same family are more similar and residuals are not indepen-
dent, cluster-robust standard errors were computed, using the CLUSTER
option.
We then investigated the associations between genetic risk status
and functional and clinical outcome. Linear regression analyses using
the XTMIXED commandwere run, using genetic risk status as indepen-
dent variable and functional (QoL or social functioning) or clinical out-
come (overall symptom-related distress) as dependent variables,
adding age and gender as covariates. Standard errors were corrected
for hierarchical clustering of the data at the family-level.
In order to study the association between the developmental course
of subclinical positive/negative symptoms on the one hand and func-
tional or clinical outcome on the other, linear regression analyses with
developmental course as independent variable and functional (QoL or
social functioning) or clinical outcome (overall symptom-related dis-
tress) as dependent variable were run for the entire sample using the
XTMIXED command. Because there were relatively few individuals
that transitioned to clinical psychosis, instead of allocating them to
four groups, resulting in small or empty groups, we divided them into
two groups (dichotomising the course-variable) resulting in a group
with persisting symptoms and a group without persisting symptoms.
For the analyses with transition as dependent variable, we performed
logistic regression analyses with developmental course containing two
levels (with/without persisting symptoms) as independent variable.
Standard errors were corrected for hierarchical clustering of the data
at the family-level. Results for the course of subclinical positive symp-
toms were corrected for the course of negative symptoms and vice
versa. Also, age and gender were added as possible confounders. For
the model of CAPE total distress (at follow-up), CAPE total distress at
baseline was added as a covariate.
Finally, in order to assess the role of genetic risk status in the subse-
quent road to impairment, the group x developmental course interac-
tion was tested in the different outcome models of positive symptoms
and negative symptoms using linear regression analyses with the
XTMIXED command as described above.
3. Results
3.1. Sample
Of the 1646 siblings and controls in the GROUP sample at baseline,
baseline and follow-up CAPE scores were available for 1131 subjects
(703 relatives and 428 controls). Due to missing values in the depen-
dent variables or covariates, sample sizes for the analyses ranged from
n = 1007 to n = 1131. See Table 1 for detailed sample characteristics.
Mean time to follow-up was 2.9 years (SD = 0.2). A contingency table
of the individuals in the positive and negative symptom categories is
presented in Table 2a (for controls) and Table 2b (siblings).
3.2. Effect of genetic risk on the course of psychotic experiences
Signiﬁcant associations were found between genetic risk status and
the developmental course of PE when correcting for age and gender,
with siblings experiencing higher levels of persisting courses of both
positive and negative symptoms compared to controls (Table 3, Model
1). When additionally correcting for the alternate symptom cluster,
only the association between genetic risk status and course of negative
symptoms remained signiﬁcant (Table 3, Model 2).
3.3. The effect of genetic risk status on clinical and functional outcome
Correcting for age and gender, signiﬁcant associations were present
between genetic risk status and functional aswell as clinical outcome at
follow-up. Genetic risk status was found to be associated with lower
levels of social functioning (B = −1.78, P b 0.001, 95% CI = −2.58;
−0.98), lower quality of life (B =−0.81, P = 0.04, 95% CI =−1.61;
−0.01) and higher overall symptom-related distress (B = 0.08, P =
0.015, 95% CI = 0.02; 0.15) at follow-up. Siblings also showed a trend
Table 1
Sample characteristics (at baseline).
Controls Siblings
(n = 428) (n =703)
Age (mean)(SD) 31.3 (10.7) 27.8 (8.0)
Gender (% male) 56 55
Education (%)
No education 0 0
Primary school 2 5
Secondary school 13 19
High school 31 21
Vocational education 44 42
University 10 13
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towards an elevated risk of developing a clinical psychosis, though this
effect did not reach statistical signiﬁcance in the current sample (OR=
2.2, 95% CI = 0.47; 10.58).
3.4. Developmental course of psychotic experiences and clinical outcome
When correcting for age, gender and the course of the alternate
symptom cluster (negative symptoms), increasing subclinical positive
symptoms were found to be associated with higher levels of overall
symptom-related distress, and persisting subclinical positive symptoms
were associated with transition to clinical psychosis (Table 4). For neg-
ative symptoms, increasing and persisting symptoms were associated
with higher levels of overall symptom-related distress, independent of
the course of positive symptoms. Persisting negative symptom course
was not independently associated with transition to psychosis
(Table 4).
3.5. Developmental course of psychotic experiences and functional outcome
Compared to the reference category (stable low) and corrected for
age, gender and negative symptoms, we found increasing and persisting
positive symptoms to be associated with both poorer social functioning
and QoL at follow-up (Table 5). For negative symptoms, we found de-
creasing, increasing and persisting negative symptoms to be associated
with poorer social functioning and QoL, independent of positive symp-
toms (Table 5).
3.6. The effect of genetic risk on the associations between course and
outcome
When examining the interaction between genetic risk status and the
developmental course of PE in themodels of functional and clinical out-
come, no signiﬁcant interactions were found (results not shown). Con-
trols and siblings did not differ signiﬁcantly in the association between
the course of positive or negative symptoms and any clinical or func-
tional outcomemeasures. For themodel of transition to clinical psycho-
sis, the interaction could not be tested due to the small amount of
individuals that transitioned (n = 10; 8 siblings, 2 controls).
4. Discussion
Themain aim of the present study was to investigate a plausible ge-
netic contribution to the proneness-persistence-impairmentmodel in a
large non-clinical sample consisting of individuals with higher genetic
risk (siblings) and lower genetic risk for psychosis (controls), separate
for subclinical positive and negative symptoms. In line with our initial
expectation, we found that siblings are more likely to experience a per-
sistent course of both positive and negative symptoms compared to
controls. Also, mostly in line with our initial expectations, we found
that sibling status and persistent course of both positive symptoms
and negative symptoms are associated with most types of clinical and
functional impairment. However, the association between persistent
course and impairment was not signiﬁcantly different in siblings com-
pared to controls.
4.1. Genetic risk status predicts course of psychotic experiences
In line with our ﬁrst expectation, the ﬁndings of the current study
show that both subclinical positive and negative symptoms are more
likely to persist in siblings of patients with a psychotic disorder com-
pared to controls. After correction for the alternate symptom cluster
(in addition to age and gender), this association remained present for
negative symptoms, but was no longer statistically signiﬁcant for posi-
tive symptoms. This may suggest that genetic vulnerability particularly
drives the course of negative symptoms, as has been proposed by
Dominguez et al. (2010). A second explanation is that genetic risk
may be (partly) associated with the co-occurrence of positive and neg-
ative symptoms,which is in linewith a proposedmultidimensional con-
struct of subclinical expression of the psychosis phenotype (e.g. Kwapil
Table 2a
Number of individuals per developmental course for controls.
Negative symptoms
Positive
symptoms
Stable
low
Decreasing Increasing Persisting Total N (%)
Stable low 350 22 22 2 385 (90.2)
Decreasing 15 1 1 2 19 (4.4)
Increasing 10 0 3 3 16 (3.7)
Persisting 4 1 1 1 7 (1.6)
Total N
(%)
379
(88.8)
24 (5.6) 16 (3.7) 8 (1.9) 427 (100)
Table 2b
Number of individuals per developmental course for siblings.
Negative symptoms
Positive
symptoms
Stable
low
Decreasing Increasing Persisting Total N (%)
Stable low 529 25 30 16 600 (85.3)
Decreasing 24 11 5 6 46 (6.5)
Increasing 11 3 7 6 27 (3.8)
Persisting 9 5 3 13 30 (4.3)
Total N
(%)
573
(81.5)
44 (6.3) 45 (6.4) 41 (5.8) 703 (100)
Table 3
Associations between genetic risk status and developmental course.
Model 1a Model 2a
RRRb 95% CI RRRb 95% CI
Positive symptomsc
Decreasing 1.46 0.85 ; 2.53 1.25 0.71 ; 2.17
Increasing 0.98 0.52 ; 1.85 0.70 0.36 ; 1.38
Persisting 2.68* 1.10 ; 6.55 1.79 0.68 ; 4.69
Negative symptomsc
Decreasing 1.15 0.69 ; 1.93 1.12 0.66 ; 1.90
Increasing 1.77 0.96 ; 3.25 1.72 0.93 ; 3.17
Persisting 3.51** 1.62 ; 7.63 2.98** 1.33 ; 6.68
* P b 0.05, ** P b 0.01
a Model 1: The association between genetic risk and course corrected for age, sex and
for clustering at the family-level. Model 2: also corrected for the alternate symptom
cluster.
b Relative Risk Ratio, representing the relative risk of experiencing a speciﬁc symptom
course for individuals with higher genetic risk (siblings) relative to individuals with lower
genetic risk (controls).
c Stable-low is used as the reference category
Table 4
Associations between developmental course and clinical outcome in the total sample
Positive symptoms Negative symptoms
Ba 95% CI Ba 95% CI
Transition to psychosis
Persisting vs
non-persisting
3.32* 0.76 ; 5.89 1.80 -0.67 ; 4.27
Total distressb
Decreasing -0.10 -0.21 ; 0.00 0.03 -0.08 ; 0.14
Increasing 0.20** 0.07 ; 0.33 0.50*** 0.39 ; 0.60
Persisting -0.05 -0.20 ; 0.09 0.56*** 0.42 ; 0.69
* P b 0.05, ** P b 0.01, *** P b 0.001
a Corrected for age, sex, clustering at the family-level and the alternate symptom cluster
b Stable-low is used as the reference category
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and Barrantes-Vidal, 2015). A third, -not mutually exclusive-
explanation may lie in the relatively high correlation between the pos-
itive and negative clusters (r = 0.50 at baseline and 0.54 at follow-up)
combinedwith the relatively low number of individuals with persistent
positive symptoms in the current sample (see Table 2a and 2b). When
corrected for the course of negative symptoms, part of the variation in
positive symptoms is also ‘ﬁltered out’. Thismay have inﬂuenced the re-
sults for positive symptomsmore than for negative symptoms, as there
were fewer individuals with persistent positive symptoms. Finally, it is
possible that the course of negative symptoms may partly reﬂect
depressive symptoms. Although adequate discriminative validity for
(subclinical) depressive and negative symptoms has been demonstrat-
ed, they are also found to be highly correlated (r = 0.72) (Stefanis
et al., 2002). Similarly, in the current study, we found high correlations
between (subclinical) negative and depressive symptoms (r = 0.71 at
baseline and 0.78 at follow-up).
4.2. Genetic risk status predicts impairment
Regarding the association between genetic risk status and impair-
ment, we found sibling status to predict lower levels of social function-
ing and lower subjective quality of life at follow-up, corrected for age en
gender. As far as we are aware, this is the ﬁrst study that links genetic
risk status for psychosis with both clinician-rated (social functioning)
and subjective functional impairment (quality of life). Unfortunately,
no data on functional outcome were available at baseline for siblings
and controls in the GROUP study, so correcting for baseline social func-
tioning and quality of life was not possible. A similar study in the patient
sample of the GROUP study, however, showed that correcting for base-
line functioning did not change the results (Janssens et al., 2016).
Additionally, we found that sibling status predicts higher overall
symptom-related distress at follow-up, when correcting for baseline
symptom-related distress, age en gender. Thisﬁnding is in linewith ear-
lier studies associating genetic risk status for psychosis with higher
stress-reactivity, e.g. a study by Myin-Germeys et al. (2001), who
found intermediate levels of emotional reactivity to stress in ﬁrst-
degree relatives of patients with psychotic disorders compared to pa-
tients and controls, and Lataster et al. (2009b), who found associations
between genetic risk status for psychosis, psychotic experiences and
reactivity to stress.
In the current study, siblings also showed a trend towards an elevat-
ed risk of developing a clinical psychosis, but this effect did not reach
statistical signiﬁcance. This may be attributed to a power problem, due
to the relatively low number of individuals who suffered ﬁrst onset of
clinical psychosis in the current sample (n = 10, 8 siblings and 2
controls). As the expression of psychotic symptoms is known to peak
in adolescence and early adulthood and decreases over time (Verdoux
et al., 1998), our relatively low rate of transitionmay have been affected
by the rather highmean age of the participants in the current study (see
Table 1).
4.3. Course of psychotic experiences predicts impairment
In line with our hypothesis, we found increasing and persistent
course of both positive and negative symptoms to be associated with
lower social functioning and quality of life,when correcting for age, gen-
der and the alternate symptom cluster. This ﬁnding is in linewith earlier
studies regarding symptom course and functional impairment (Cohen
and Davis, 2009; Dominguez et al., 2011; Kaymaz et al., 2012; Kwapil
et al., 2013; De Loore et al., 2011; Rossler et al., 2007; Wigman et al.,
2011b). Additionally, we found that decreasing negative symptoms
were associated with more functional impairment at follow-up, com-
pared to individuals with stable low negative symptoms. This suggests
that having experienced negative symptoms (in spite of potential
‘recovery’ from these negative symptoms)may still serve as a risk factor
for functional impairment. This is in line with the hypothesis by
Dominguez et al. (2010) that negative symptoms may be associated
with earlier developmental impairment.
Increasing course of positive and negative symptoms and persisting
course of negative symptoms, but not positive symptoms,were found to
be associated with overall symptom-related distress. The latter ﬁnding
may indicate habituation to psychotic experiences in termsof emotional
response, but could also be explained by a power problem due to the
relatively low number of individuals with persistent positive symptoms
in the current sample, as has been mentioned before. Furthermore, we
found that persisting positive, but not persisting negative symptoms,
were independently associated with transition to clinical psychosis.
This may be explained by construct overlap between subclinical and
clinical psychosis, and the well documented fact that clinical psychosis
is usually preceded by persistent subclinical positive symptoms
(Cougnard et al., 2007; Dominguez et al., 2011; Wigman et al., 2011a;
Wigman et al., 2011b).
4.4. No interaction between genetic risk status and course for levels of
impairment
In contrastwith our expectation, no signiﬁcant interaction effectwas
found between genetic risk status and course in the prediction of im-
pairment, indicating that once an individual experiences persistent
symptoms, both siblings and controls are equally at risk of develop-
ing clinical (in terms of symptom-related distress) and functional
impairment. This ﬁnding underscores the validity of the proneness-
persistence-impairment model, in individuals with both higher and
lower genetic risk for psychosis.
4.5. Methodological considerations
Several potential limitations of the current study have been touched
on earlier in the Discussion section. For one, some of the ﬁndings of the
current studymay have been limited by statistical power problems, due
to the relatively low number of individuals who experienced persistent
positive symptomsandwho transitioned to clinical psychosis in the cur-
rent sample. Other aforementioned potential limitations are the lack of
correction for (the course of) depressive symptoms mainly in regard to
(the course of) negative symptoms, and the lack of feasibility to correct
for baseline functional impairment.
Furthermore, phenomenology alone using a self-report measure
may not fully capture the vulnerability for schizophrenia-spectrum pa-
thology, as has been mentioned, for instance, by Thaker et al. (1996).
Also, developmental course of psychotic experiences was currently
assessed at two time-points. Variation in severity of psychotic experi-
ences within-subjects in between time-points is possible. Still, when
at two ‘random’ time-points the severity of psychotic experiences is
high, it is likely that these experiences are more persistent over time
(i.e. of high severity all the time or a large percentage of time). Finally,
as has been mentioned in the Introduction section, so far many terms
have been developed to reﬂect vulnerability for schizophrenia-spectrum
Table 5
Associations between developmental course and functional outcome.
Social functioning Quality of life
Ba 95% CI Ba 95% CI
Positive symptomsb
Decreasing -0.93 -2.42 ; 0.57 -0.46 -0.99 ; 0.07
Increasing -4.32*** -6.16 ; -2.49 -1.38*** -2.04 ; -0.73
Persisting -2.69** -4.71 ; -0.67 -1.20** -1.92 ; -0.47
Negative symptomsb
Decreasing -3.28*** -4.73 ; -1.83 -1.11*** -1.63 ; -0.59
Increasing -5.43*** -6.73 ; -3.88 -2.05*** -2.60 ; -1.50
Persisting -9.29*** -11.09 ; -7.49 -3.59*** -4.24 ; -2.95
** P b 0.01,*** P b 0.001
a Corrected for age, sex, clustering at the family-level and the alternate symptom cluster
b Stable-low is used as the reference category.
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pathology, yet general consensus on the operationalization of terms is
lacking. In response to the this issue, authors have recently called for
the need of development of amultidimensional model unifying all symp-
toms constructs that represent vulnerability for schizophrenia-spectrum
pathology (Kwapil and Barrantes-Vidal, 2015). The results of the current
study underline the importance of assessing psychotic experiences in
the context of genetic risk, multidimensional (including both subclinical
positive and negative symptoms) and over time.
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